Clinical Trials for Cancer Type: Corpus Uteri

10 Open Trials. Phone:(877.827.8839)
Protocol No. Title Status
ECOG-EAY131 (CIRB) Molecular Analysis for Therapy Choice (MATCH) Open
GOG-0286B (CIRB) A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Open
SWOG-S1609 (CIRB) DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Open
UCI-13-09 Molecular Analysis of Alterations of the PI3K/AKT/mTOR Pathway in Lynch Syndrome-Associated Endometrial Cancer with Clinicopathologic Correlation Open
UCI-15-78 An Open-Label, Phase I/II, Dose-Escalation Study Evaluating The Safety And Tolerability of GDC-0032 In Patients With Locally Advanced Or Metastatic Solid Tumors Or Non-Hodgkin's Lymphoma And In Combination With Endocrine Therapy In Patients With Locally Advanced Or Metastatic Hormone Receptor-Positive Breast Cancer Open
UCI-16-52 A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation Open
UCI-16-53 FOCUS: A Multicenter, Multinational, Double-blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy (PCC) (Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects with Platinum-Resistant, Recurrent, Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Open
UCI-16-69 ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Open
UCI-16-71 A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors Open
UCI-16-96 A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Open